Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases ; volume:15 ; number:1 ; day:1 ; month:5 ; year:2017 ; pages:1-12 ; date:12.2017
Journal of translational medicine ; 15, Heft 1 (1.5.2017), 1-12, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Zoppoli, Gabriele
- Beteiligte Personen und Organisationen
-
Garuti, Anna
Cirmena, Gabriella
Cantogno, Ludovica Verdun di
Botta, Cristina
Gallo, Maurizio
Ferraioli, Domenico
Carminati, Enrico
Baccini, Paola
Curto, Monica
Fregatti, Piero
Isnaldi, Edoardo
Lia, Michela
Murialdo, Roberto
Friedman, Daniele
Sapino, Anna
Ballestrero, Alberto
SpringerLink (Online service)
- DOI
-
10.1186/s12967-017-1195-7
- URN
-
urn:nbn:de:1111-201705121423
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zoppoli, Gabriele
- Garuti, Anna
- Cirmena, Gabriella
- Cantogno, Ludovica Verdun di
- Botta, Cristina
- Gallo, Maurizio
- Ferraioli, Domenico
- Carminati, Enrico
- Baccini, Paola
- Curto, Monica
- Fregatti, Piero
- Isnaldi, Edoardo
- Lia, Michela
- Murialdo, Roberto
- Friedman, Daniele
- Sapino, Anna
- Ballestrero, Alberto
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Is HER2 amplification predictable by digital immunohistochemistry?
Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues
Amplification of HER2 is a marker for global genomic instability
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression
A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Is HER2 amplification predictable by digital immunohistochemistry?
Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues
Amplification of HER2 is a marker for global genomic instability
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression
A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Is HER2 amplification predictable by digital immunohistochemistry?
Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues
Amplification of HER2 is a marker for global genomic instability
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression
A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results